This site provides INTERCEPT product information for Health Care Professionals in the United States.

Webinars and Podcasts

Back to resources

INTERCEPT® Fibrinogen Complex Experience in Cardiac Surgery at UVA

Timely administration of fibrinogen and other key clotting factors is essential to controlling hemorrhage, yet access to fibrinogen sources (such as cryo AHF and fibrinogen concentrates) can be challenging given their long wait times and short shelf life.

This webinar discusses the importance of fibrinogen replacement in cardiac surgery, the difference between INTERCEPT® Fibrinogen Complex (IFC), cryo AHF and fibrinogen concentrates, and UVA Health’s experience with IFC, including how IFC’s immediate availability* is improving patient access and impacting patient care.

John McNeil, MD, FASE
Division Chief, Cardiothoracic Anesthesia
University of Virginia Health
Charlottesville, Virginia

Dr. John McNeil is the Division Chief for Cardiothoracic Anesthesia and a tenured Associate Professor of Anesthesiology at UVA Health. He is board-certified in adult cardiac anesthesiology, anesthesiology and transesophageal echocardiography. He is also a Fellow of the American Society of Echocardiography (FASE).

Dr. McNeil is originally from Fairfax, Virginia, and earned his medical degree from UVA. He completed his residency in anesthesiology at Beth Israel Deaconess Medical Center in Boston, and his fellowship in adult cardiothoracic anesthesia at The Johns Hopkins School of Medicine in Baltimore.

His interests include coagulation, echocardiography, pulmonary complications, OR efficiency and education.

MKT-EN 00835
MKT-EN 00863

Watch the Replay
Runtime: 22 min

INTERCEPT® Blood System for Platelets Pathogen Reduction System

INTENDED USE

The INTERCEPT Blood System for Platelets is intended to be used for ex vivo preparation of pathogen-reduced Amicus apheresis platelet components suspended in 65% PAS-3/35% plasma, and Trima apheresis platelet components suspended in 100% plasma in order to reduce the risk of transfusion-transmitted infection (TTI), including sepsis, and as an alternative to gamma irradiation for prevention of transfusion-associated graft versus host disease (TA-GVHD).

CONTRAINDICATIONS

Contraindicated for preparation of platelet components intended for patients with a history of hypersensitivity reaction to amotosalen or other psoralens.

Contraindicated for preparation of platelet components intended for neonatal patients treated with phototherapy devices that emit a peak energy wavelength less than 425 nm, or have a lower bound of the emission bandwidth <375 nm, due to the potential for erythema resulting from interaction between ultraviolet light and amotosalen.

WARNINGS AND PRECAUTIONS

Only INTERCEPT Processing Sets for platelets are approved for use in the INTERCEPT Blood System. Use only the INTERCEPT INT100 Illuminator for UVA illumination of amotosalen-treated platelet components. No other source of UVA light may be used. Please refer to the Operator’s Manual for the INT100 Illuminator. Discard any platelet components not exposed to the complete INT100 illumination process.

Tubing components and container ports of the INTERCEPT Blood System contain polyvinyl chloride (PVC). Di(2-ethylhexyl)phthalate (DEHP) is known to be released from PVC medical devices, and increased leaching can occur with extended storage or increased surface area contact. Blood components will be in contact with PVC for a brief period of time (approx. 15 minutes) during processing. The risks associated with DEHP released into the blood components must be weighed against the benefits of therapeutic transfusion.

INTERCEPT® Blood System for Cryoprecipitation for the manufacturing of Pathogen Reduced Cryoprecipitated Fibrinogen Complex

INTENDED USE
The INTERCEPT Blood System for Cryoprecipitation is intended to provide a functionally closed system for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex.

Pathogen Reduced Cryoprecipitated Fibrinogen Complex is indicated for:

Treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency.
Control of bleeding when recombinant and/or specific virally inactivated preparations of factor XIII or von Willebrand factor (vWF) are not available.
Second-line therapy for von Willebrand disease (vWD).
Control of uremic bleeding after other treatment modalities have failed.

Limitations of Use: Pathogen Reduced Cryoprecipitated Fibrinogen Complex should not be used for replacement of factor VIII.

CONTRAINDICATIONS

Contraindicated for preparation of blood components intended for patients with a history of hypersensitivity reaction to amotosalen or other psoralens.

Contraindicated for preparation of blood components intended for neonatal patients treated with phototherapy devices that emit a peak energy wavelength less than 425 nm, or have a lower bound of the emission bandwidth <375 nm, due to the potential for erythema resulting from interaction between ultraviolet light and amotosalen.

WARNINGS AND PRECAUTIONS

Only the INTERCEPT Blood System for Cryoprecipitation is approved for use to produce Pathogen Reduced Cryoprecipitated Fibrinogen Complex.

For management of patients with vWD or factor XIII deficiency, Pathogen Reduced Cryoprecipitated Fibrinogen Complex should not be used if recombinant or specific virally-inactivated factor preparations are available. In emergent situations, if recombinant or specific virally-inactivated factor preparations are not available, Pathogen Reduced Cryoprecipitated Fibrinogen Complex may be administered.